

**MISSISSIPPI DIVISION OF MEDICAID
DRUG UTILIZATION REVIEW (DUR) BOARD
MINUTES OF THE DECEMBER 8, 2022 MEETING**

DUR Board Roster: State Fiscal Year 2023 (July 1, 2022 – June 30, 2023)	Mar 2022	Jun 2022	Sep 2022	Dec 2022
Joseph Austin, MD	NA	NA	✓	✓
Lauren Bloodworth, PharmD	✓			
Terrence Brown, PharmD	✓	✓	✓	✓
Patrick Bynum, MD	✓	✓	✓	✓
Chrysanthia Davis, PharmD	NA	NA	✓	✓
Tanya Fitts, MD	✓	✓	✓	
Jahanzeb Khan, MD	NA	NA	✓	✓
Ray Montalvo, MD			✓	
Holly Moore, PharmD		✓	✓	✓
Kristi Phelps, RPh	NA	NA	✓	✓
Joshua Pierce, PharmD	✓	✓	✓	✓
Bobbie West, MD	NA	NA	✓	
TOTAL PRESENT**	9	7	11	8

*** Total Present may not be reflected by individual members marked as present above due to members who either resigned or whose terms expired being removed from the list.*

Also Present:

Division of Medicaid (DOM) Staff:

Terri Kirby, RPh, CPM, Pharmacy Director; Dennis Smith, RPh, DUR Coordinator; Gail McCorkle, RPh, Clinical Pharmacist; Chris Yount, MA, PMP, Staff Officer – Pharmacy;

University of Mississippi School of Pharmacy - MS-DUR Staff:

Eric Pittman, PharmD, MS-DUR Project Director; Kaustuv Bhattacharya, PhD, Research Assistant Professor;

Change Healthcare Staff:

Paige Clayton, PharmD, On-Site Clinical Pharmacist; Shannon Hardwick, RPh, CPC Pharmacist;

Coordinated Care Organization (CCO) Staff:

Jenni Grantham, PharmD, Director of Pharmacy, Magnolia Health; Heather Odem, PharmD, Director of Pharmacy - Mississippi, UnitedHealthcare Community & State; Trina Stewart, PharmD, Pharmacy Manager, Molina Healthcare;

Gainwell Staff:

Ashleigh Holeman, MS Pharmacy Services Manager; Tricia Banks, PharmD, MS Clinical Pharmacist; Lew Anne Snow, RN, Advisor Business Analyst;

Alliant Health Staff:

Catherine Brett, MD, Quality Director, MS UM/QIO; Buddy Ogletree, PharmD, Pharmacist;

Visitors:

Keana Dandridge, Novartis; Shawn Headley, Gilead; Cathy Prine-Eagle, Merck; Paula Whatley, Novo Nordisk; Daniel Field, Capital Resources.

Call to Order/Welcome:

Dr. Brown called the meeting to order at 1:00 pm.

OLD BUSINESS:

Dr. Bynum moved to approve the minutes from the September 2022 DUR Board Meeting, seconded by Dr. Davis, and unanimously approved by the DUR Board.

Resource Utilization Review:

Dr. Pittman presented the resource utilization report for July 2022. Dr. Pittman provided an overview of the resource utilization report and highlighted trends identified in each section.

NEW BUSINESS:

Update on MS-DUR Educational Interventions:

Dr. Pittman provided an overview of all DUR mailings and educational notices that occurred between September 2022 – November 2022.

Special Analysis Projects:

Assessment of Predictors of Severe Maternal Morbidity (SMM) Among Pregnant Medicaid Beneficiaries – Follow-up Analysis

From the follow-up analysis it was found the driving MCI conditions among pregnant beneficiaries experiencing SMM events as compared to those that did not experience SMM events included pre-existing hypertension and previous cesarean birth, followed by pre-existing diabetes mellitus, drug abuse, gestational hypertension, and asthma. It was also found that pregnant beneficiaries experiencing SMM events traveled further distances for both usual prenatal care and delivery compared to those that did not experience SMM events. These findings can be used to help Medicaid provide improved maternal care and reduce instances of SMM.

The following recommendations were presented:

1. MS-DUR should complete the ROC curve analysis to determine an MCI cut-off score.
2. MS-DUR should further examine differences in provider types, types of transportation services provided, and care provided during the first trimester between cases and controls.

3. DOM is encouraged to seek opportunities to disseminate findings from this study and to collaborate with other stakeholders in maternal health across Mississippi such as the MSDH and the March of Dimes.

Following a robust discussion, Dr. Bynum made a motion to accept the recommendations, seconded by Dr. Pierce, and unanimously approved by the Board.

COVID-19 Overview Among Medicaid Beneficiaries

The COVID-19 global pandemic has had a tremendous impact on healthcare around the world. In Mississippi, many Medicaid beneficiaries have been infected with the virus. This report provided baseline descriptive characteristics of Medicaid beneficiaries diagnosed with COVID-19 and trends in the uptake of COVID-19 vaccines and therapeutic agents.

This report for the DUR Board on COVID-19 was for information and discussion purposes only. No action was sought as a result of this report.

Impact of Obesity Among Medicaid Beneficiaries

Obesity is a common, chronic disease with a complex pathophysiology that impacts an increasing proportion of the U.S. population. By 2030, adult obesity is projected to affect 58.2% of the population in Mississippi. Common comorbidities associated with obesity such as hypertension, diabetes, coronary artery disease, osteoporosis, and others contribute to the enormous health and economic burdens attributed to obesity. The burdens associated with obesity coupled with recent changes in the pharmacotherapeutic landscape of obesity management present an opportunity for the Division of Medicaid to examine its current policies regarding obesity management.

The following recommendations were presented:

1. DOM is encouraged to consider changing policies pertaining to medication coverage for the management of obesity.
2. DOM is encouraged to ask the P&T Committee to conduct a therapeutic class review of anti-obesity medications.
3. DOM is encouraged to consider conducting a detailed economic impact evaluation to determine the impact of coverage of anti-obesity medications.
4. DOM should consider a phased-in approach to medication coverage exploring options based on data presented in the report. This approach could be developed around factors such as obesity classification, age, or presence of comorbidities.
5. MS-DUR is encouraged to examine trends in healthcare utilization costs for those individuals initiated on GLP1-RAs and SGLT2 Inhibitors without a diagnosis of diabetes present in claims data.

Following a robust discussion, Dr. Pierce made a motion to accept the recommendations, seconded by Ms. Phelps, and unanimously approved by the Board.

FDA Drug Safety Updates:

Dr. Pittman presented FDA drug safety communications for September 2022 – November 2022.

Pharmacy Program Update:

Ms. Kirby provided a pharmacy program update highlighting the recent transition to their new fiscal agent, Gainwell. Ms. Kirby encouraged the Board to provide feedback regarding any issues they may encounter and to be aware of pharmacy updates that occur.

Next Meeting Information:

The Board was presented with potential 2023 meeting dates. They were asked to review those dates for possible conflicts. A follow-up email will be sent out to the Board confirming the 2023 dates.

Dr. Pierce motioned to adjourn the meeting at 2:35 pm, seconded by Dr. Moore, and unanimously approved by the Board.

Submitted,

Eric Pittman, PharmD
Evidence-Based DUR Initiative, MS-DUR

The screenshot shows a web page titled "PUBLIC MEETING NOTICES" with a header for "Mississippi Public Meeting Notices". The main content area is titled "NOTICE DETAILS" and contains the following information:

- State Agency:** Division of Medicaid
- Public Body:** Division of Medicaid
- Title:** Drug Utilization Review Board Meeting
- Subject:** Drug Utilization Review Board
- Date and Time:** 12/8/2022 1:00:00 PM
- Description:** Please see attachment regarding Drug Utilization Review Board meeting.

On the right side of the page, there are three sections:

- MEETING LOCATION:** 501 N. West Street, Jackson MS 39201. Includes a "Map this!" link.
- CONTACT INFORMATION:** Chris Yount, 6013596336, christopher.yount@medicaid.ms.gov
- DOWNLOAD ATTACHMENTS:** DFA Meeting notification 2022.docx (Added 1/4/2022)
- SUBSCRIPTION OPTIONS:** Subscription options will send you alerts regarding future notices posted by this public body. Includes an RSS link.

A "Back" button is located at the bottom left of the notice details section.

Meeting Location: Woolfolk Building, 501 North West Street, Conference Room 145, Jackson, MS 39201, unless otherwise noted by the corresponding date of the meeting listed below.

Contact Information: Office of Pharmacy:

Chris Yount, 601-359-5253; Christopher.yount@medicaid.ms.gov, or
Jessica Tyson, 601-359-5253; Jessica.Tyson@medicaid.ms.gov

Notice details:

State Agency: MS Division of Medicaid

Public Body: Drug Utilization Board (DUR) Meeting

Subject: Quarterly Meeting

Dates and Times:

2022 dates:

- March 3, 2022 (1-3pm; Room 117, Woolfolk Building)
- June 9, 2022 (1-3pm; Room 145)
- September 15, 2022 (1-3pm; Room 145)
- December 8, 2022 (1-3pm; Room 145)

Description: The Mississippi Division of Medicaid's Drug Utilization Review (DUR) Board is a quality assurance body which seeks to assure appropriate drug therapy to include optimal beneficiary outcomes and appropriate education for physicians, pharmacists, and the beneficiary. The Drug Utilization Review (DUR) Board is composed of twelve participating physicians and pharmacists who are active MS Medicaid providers and in good standing with their representative organizations.

The Board reviews utilization of drug therapy and evaluates the long-term success of the treatments.

The Drug Utilization Review (DUR) Board meets quarterly.

[DUR Board Registration for December 8, 2022 now open \(live meeting, no virtual options\)](#)

Registration for the December 8, 2022 Drug Utilization Review board meeting is now open. Registration is limited to one representative per company. Agenda will be posted approximately one week prior to event date. Meeting information and registration link are provided below. Please email DOMPharmacyOffice@medicaid.ms.gov with any questions.

Meetings

Meetings will be held at 1:00 pm in Woolfolk Building Room 145 unless otherwise noted. 2022 dates are as follows:

- ~~March 3, 2022;~~
- ~~June 9, 2022;~~
- ~~September 15, 2022 (1pm); and,~~
- December 8, 2022 (1pm)

Important Updates: Beginning October 1, 2021, pharmaceutical and industry members, vendors, and general public must register to attend. Registration will open thirty (30) days prior to the meeting date. Registration will close at 12pm (noon) the day before the meeting. Due to the ongoing pandemic, *only one representative per company may register/attend.* Public speaking is not allowed at DUR meetings unless called on by the Board.

Parking: parking may be found on the perimeter of the Woolfolk Building, on the north side of the Woolfolk Building located at the old Wright and Ferguson building (yellow/brown building), and at the Division of Medicaid and First Baptist Church main parking lots at the corner of High Street and North President Street. *Guests may not park at the Woolfolk Building or in any parking space marked "Reserved".*



CLICK HERE to register online! You must register to attend DUR Board meetings.

NOTE: Registration is **required** for all pharmaceutical industry and advocacy representatives to be able to attend DUR Board meetings.

Companies that have meet the one rep per company registration limit as of December 1, 2022:

1. Alliant
2. American Cancer Society
3. Biogen
4. Gilead
5. Grifols
6. Merck
7. Novartis
8. Novo Nordisk
9. Vertex